The Right Partner for Biosimilar Success
The biosimilar industry is unforgiving, and only those with the right experience and strategies succeed. If you're looking for more than just consulting—if you need a partner who has been through it all and knows how to win—I am here to help. Whether you need to prepare for a launch, develop a portfolio, or build long-term resilience, BIG can deliver the tailored advisory solutions you need to thrive.
The BIG Difference
-
With over 15 years of leadership at industry pioneers like Biogen, Celltrion USA, and Alvotech, BIG brings unmatched expertise to the biosimilars market. Our proven track record in successful launches and market access strategies sets us apart in a field where few truly excel.
-
At BIG, information is at the heart of everything we do. We employ analysis to interpret market trends, payer behaviors, and competitive landscapes, providing you with data-driven strategies that form a solid foundation for success.
-
Our deep understanding of the biosimilars landscape allows us to generate actionable insights unique to each launch. We help you identify opportunities and anticipate challenges, guiding you through complexities with clarity and confidence.
-
Leverage BIG's extensive network of established relationships within industry. Our connections facilitate collaboration and open doors to create new business opportunities.
-
BIG doesn't just consult—we lead. Our expertise in aligning teams can bring sustained performance and talent retention, driving execution excellence aligned with your biosimilar objectives.
Let’s work together
Key Learnings from more than 15 Years of US Biosimilar market experience
-
Every Biosimilar Launch is Unique
No two biosimilar launches are the same, making it difficult to create standardized approaches or replicate success. Each product faces distinct challenges, from varying regulatory landscapes to different competitive dynamics and payer behaviors. To succeed, companies need to develop fresh market insights, build customized strategies, and execute precise tactics for every launch—often without the benefit of efficiencies gained in traditional pharmaceutical markets.
-
Internal Alignment is Critical
Aligning a biosimilar strategy with a company’s mission, portfolio, and core competencies is crucial—but it’s often easier said than done. Biosimilars don’t always fit neatly into existing business models, creating friction in prioritization and resource allocation. Organizations that successfully launch biosimilars ensure that their teams are unified around a clear, strategic positioning, with internal alignment across marketing, sales, and market access teams to support smooth execution.
-
Resources and Expertise Drive Biosimilar Success
The U.S. biosimilar market demands both strategic investment and deep expertise—without them, even the most promising products can falter. Companies must invest in market access strategies, commercialization teams, and analytics to ensure successful entry and growth. Beyond financial resources, success also requires knowing where to focus efforts and having the right talent in place to navigate the complexities of biosimilar adoption.
-
Crafting the Right Target Product Profile
Developing a biosimilar isn't just about replicating a biological product; it's about meeting the specific needs and expectations of healthcare providers and patients. Building the right target product profile means identifying and delivering the critical attributes that matter most—such as indications, dosage forms, and administration methods. Missing these key elements can significantly impact market performance, making it essential to align product development closely with customer priorities.
-
Navigating Uncertainty
The biosimilars market is characterized by constant change and unpredictability, which can challenge even the most resilient teams. Maintaining motivation during times of ambiguity is crucial for continued performance and talent retention. Leaders must cultivate a supportive environment, finding innovative ways to inspire their teams and keep them focused—even when the path forward isn't clearly defined.
-
Bridging the Knowledge Gap
A widespread lack of understanding about biosimilars can hinder a company's ability to compete effectively. Many professionals may be familiar with one biosimilar but fail to grasp the significant differences each new product and market can present. Continuous education and training at all organizational levels—from executives to field teams—are essential to develop the expertise needed to navigate unique challenges and capitalize on opportunities